So far, we listed 39 abstracts from the European listed biotech companies or their partners for the ASH 2019 Annual meeting, excluding those relating to daratumumab (16 abstracts by Janssen/JNJ). Morphosys will present 7 abstracts and Oncopeptides 6. Cellectis and partners gather 4 presentations. Argenx will have 2 oral presentations, one for efgartigimod in ITP,[…]